Abbott to Acquire Visiogen and Enlarge Ophthalmic Portfolio
September 8, 2009
Abbott has announced an agreement to acquire Visiogen, Inc. for $400 million in cash. This acquisition provides the company with a next-generation IOL technology that addresses presbyopia for cataract patients.
Visiogen’s accommodating IOL, called Synchrony, is designed to deliver improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity. The Synchrony accommodating IOL is a significant advancement in artificial lens technology and is designed to mimic accommodation.
Synchrony has received CE mark designation and has been available commercially in Europe since January 2009. It also is currently under review by the U.S. Food and Drug Administration.
Read the release.
You might also enjoy...
- Visiogen Raises $40 Million to Support Global to Support the Global Commercialization of the Synchrony Dual Optic Accommodating Intraocular Lens
- Will New “Dual Optic” Accommodating Intraocular Lens Provide Better Outcomes for Cataract Patients?
- FDA Approves Marketing of Crystalens HD(TM) in Quarter Diopter Steps by Bausch & Lomb in the United States
- Synchrony IOL Gives Almost 3D of Accomodation
- Alcon AcrySof® IQ Toric IOL Approved for U.S. Patients with Cataracts and Astigmatism
Comments
Jump down to form below to submit your own comments
Subscribe for Free!
